
NTHI Stock Forecast & Price Target
NTHI Analyst Ratings
Bulls say
NeOnc Technologies Hldgs is well-positioned for success in the biotech industry, with a strong focus on addressing unmet needs in CNS tumor treatment, a promising drug pipeline, and a solid financial outlook. The company's approach to using a natural compound like POH and developing novel agents shows a commitment to innovative solutions. Additionally, their reported positive financials and funding until 2026 provide a stable foundation for continued growth and expansion. With a potential for accelerated approval and a promising mechanism of action, NeOnc's drugs have the potential to make a significant impact on the lives of patients with CNS tumors and their ultimate goal aligns with the needs of the market.
Bears say
NeOnc Technologies Hldgs is facing several key challenges that could impact its success in the competitive biopharmaceutical industry. These include potential commercial and political risks that could lead to higher prices for its potentially lifesaving treatments, as well as technical risk related to the distribution of its drug in the central nervous system. In addition, concerns around the potential long-term safety and tolerability of its lead product candidates, NEO100 and NEO212, could lead to increased scrutiny and potential limited use of these therapies, limiting the company's potential for success in the market.
This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
NTHI Analyst Forecast & Price Prediction
Start investing in NTHI
Order type
Buy in
Order amount
Est. shares
0 shares